Five things for pharma marketers to know: Friday, June 24, 2016



1. Britain has voted to leave the European Union, a stunning decision that will create regulatory uncertainty for drugmakers. The European equivalent of the FDA, the London-based European Medicines Agency, is expected to have to relocate. GlaxoSmithKline, the largest British drugmaker, said the vote “creates uncertainty and potentially complexity for us in the future.” (Reuters)

2. Evercore ISI analyst Mark Schoenebaum wrote in an investor note that only a small percentage of pharma companies' sales come from the U.K. Pfizer, Merck, AbbVie, Bristol-Myers Squibb, Lilly and Gilead generate less than 5% of their revenues from the U.K., according to his firm's analysis.

3. President Barack Obama said he will veto a bill allowing people to purchase over-the-counter medications with their health savings accounts. The bill, H.R. 1270, would repeal the section of the Affordable Care Act that forbids consumers from using health savings accounts, health reimbursement accounts, or flexible spending accounts to purchase OTC medications. (Modern Healthcare)

4. A new analysis published in JAMA Cardiology found that adoption of Novartis' heart-failure drug Entresto could prevent more than 28,000 deaths per year. (JAMA)

5. AstraZeneca and Teva settled a patent dispute over diabetes injection Byetta. AZ granted Teva a license to commercialize its generic version of the drug. (The Street)